Cocrystal Pharma Develops Novel Ebola Screening Technology

BOTHELL, WA -- (Marketwired) -- 10/23/14 -- Cocrystal Pharma, Inc. (OTCBB: COCP), a biotechnology company developing new antiviral therapeutics for human diseases, today reported that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.

Cocrystal utilized its core platform technology to develop the in vitro test.

According to Cocrystal Chief Scientist, Dr. Roger Kornberg, "We are very excited to have cloned the gene, purified and characterized its product, and integrated the gene product into our high-throughput platform. We believe we are the first group to have developed a novel screening methodology that can accurately identify inhibitors, which are potential drug candidates." 

To learn more about the company go to our webpage at

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a pharmaceutical company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal Pharma employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies and our market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. Cocrystal has previously received strategic investments from Teva Pharmaceuticals, OPKO Health (NYSE: OPK) and The Frost Group. OPKO Health and The Frost Group together own approximately 48% of Cocrystal.

MDM Worldwide
David Zazoff

Source: Cocrystal Pharma, Inc.